MX2021003261A - Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno. - Google Patents

Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno.

Info

Publication number
MX2021003261A
MX2021003261A MX2021003261A MX2021003261A MX2021003261A MX 2021003261 A MX2021003261 A MX 2021003261A MX 2021003261 A MX2021003261 A MX 2021003261A MX 2021003261 A MX2021003261 A MX 2021003261A MX 2021003261 A MX2021003261 A MX 2021003261A
Authority
MX
Mexico
Prior art keywords
clostridial neurotoxin
chain clostridial
activation loop
chain
clostridial neurotoxins
Prior art date
Application number
MX2021003261A
Other languages
English (en)
Inventor
Laura Lovelock
Adam Kupinski
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of MX2021003261A publication Critical patent/MX2021003261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21009—Enteropeptidase (3.4.21.9), i.e. enterokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para procesar proteolíticamente una neurotoxina clostridial monocatenaria en una neurotoxina clostridial bicatenaria correspondiente, el método comprende: proporcionar una neurotoxina clostridial monocatenaria; y poner en contacto la neurotoxina clostridial monocatenaria con una enteroquinasa o el factor Xa; donde la neurotoxina clostridial monocatenaria tiene un bucle de activación que comprende la secuencia de polipéptidos Cys-(Xaa)a-Ile-Asp/Glu-Gly-Arg-(Yaa)b-Cys (SEC. ID NO.: 1), donde a = 1-10 y b = 4-15; y en el que la enteroquinasa o el factor Xa hidroliza un enlace del péptido del bucle de activación produciendo así una neurotoxina clostridial bicatenaria. La invención también se refiere a neurotoxinas clostridiales diseñadas por ingeniería y a métodos para fabricar las mismas, así como a composiciones farmacéuticas, secuencias de nucleótidos y usos terapéuticos relacionados.
MX2021003261A 2018-09-28 2019-09-27 Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno. MX2021003261A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1815817.0A GB201815817D0 (en) 2018-09-28 2018-09-28 Clostridial neurotoxins comprising and exogenous activation loop
PCT/GB2019/052732 WO2020065336A1 (en) 2018-09-28 2019-09-27 Clostridial neurotoxins comprising an exogenous activation loop

Publications (1)

Publication Number Publication Date
MX2021003261A true MX2021003261A (es) 2021-05-12

Family

ID=64108972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003261A MX2021003261A (es) 2018-09-28 2019-09-27 Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno.

Country Status (15)

Country Link
US (1) US20220211823A1 (es)
EP (1) EP3856232A1 (es)
JP (2) JP7511549B2 (es)
KR (1) KR20210068476A (es)
CN (1) CN113164565A (es)
AU (1) AU2019348732C1 (es)
BR (1) BR112021005017A2 (es)
CA (1) CA3111962A1 (es)
EA (1) EA202190889A1 (es)
GB (1) GB201815817D0 (es)
IL (1) IL281814A (es)
MX (1) MX2021003261A (es)
SG (1) SG11202102323TA (es)
TW (1) TW202027782A (es)
WO (1) WO2020065336A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017292922B9 (en) * 2016-07-08 2022-05-12 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CA3213914A1 (en) 2021-03-30 2022-10-06 Mikhail KALINICHEV Treatment of pain & inflammatory disorders
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
CN115785237B (zh) * 2022-09-01 2023-06-16 上海蓝晶生物科技有限公司 一种重组肉毒杆菌毒素及其制备方法
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214229D0 (en) * 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
CN118126143A (zh) * 2024-03-14 2024-06-04 河北平朴生物科技合伙企业(有限合伙) 一种a型肉毒毒素的突变体及其应用
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
ES2187200T3 (es) 1998-05-13 2003-05-16 Biotecon Ges Fur Biotechnologi Proteina hibrida para inhibir la desgranulacion de mastocitos y su uso.
DK1098664T3 (da) 1998-07-22 2003-11-17 Osprey Pharmaceuticals Ltd Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
EP1700918B1 (en) 1999-08-25 2014-01-15 Allergan, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
AU2005311086B2 (en) 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ATE518882T1 (de) 2005-09-19 2011-08-15 Allergan Inc Mit clostridientoxin aktivierbare clostridientoxine
US20090269358A1 (en) * 2005-10-07 2009-10-29 Shone Clifford C Proteins with Improved Solubility and Methods for Producing and Using Same
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
AU2007272517B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008008803A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
ES2732205T3 (es) * 2008-06-12 2019-11-21 Ipsen Bioinnovation Ltd Proteínas de fusión para uso en el tratamiento del cáncer
GB0815264D0 (en) 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
EP2373294B1 (en) * 2008-12-10 2016-04-20 Allergan, Inc. Clostridial toxin pharmaceutical compositions
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
EP2419128B1 (en) 2009-04-14 2018-06-06 Medical College of Wisconsin, Inc. Engineered botulinum neurotoxin
CZ302526B6 (cs) * 2010-05-13 2011-06-29 Zentiva, K.S. Rekombinantní produkce teriparatidu v bakteriích Escherichia coli
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
HUE053935T2 (hu) * 2015-01-09 2021-08-30 Ipsen Bioinnovation Ltd Kationos neurotoxinok
AU2017292922B9 (en) 2016-07-08 2022-05-12 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives

Also Published As

Publication number Publication date
CN113164565A (zh) 2021-07-23
EA202190889A1 (ru) 2021-11-10
JP2022512573A (ja) 2022-02-07
AU2019348732B2 (en) 2024-02-15
GB201815817D0 (en) 2018-11-14
TW202027782A (zh) 2020-08-01
BR112021005017A2 (pt) 2021-06-08
KR20210068476A (ko) 2021-06-09
CA3111962A1 (en) 2020-04-02
JP7511549B2 (ja) 2024-07-05
WO2020065336A1 (en) 2020-04-02
AU2019348732C1 (en) 2024-08-29
US20220211823A1 (en) 2022-07-07
SG11202102323TA (en) 2021-04-29
JP2024012421A (ja) 2024-01-30
EP3856232A1 (en) 2021-08-04
IL281814A (en) 2021-05-31
AU2019348732A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
MX2021003261A (es) Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno.
MX2019007024A (es) Proteasas de degradacion de plastico mejoradas.
MX2020006359A (es) Nuevas proteasas y usos de las mismas.
MX2020005324A (es) Microorganismo modificado geneticamente para producir acido 3-hidroxidadipico, acido alfa-hidromuconico y/o acido adipico, y metodo de produccion para tales productos quimicos.
AR114339A1 (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
SA520412669B1 (ar) تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
MY187542A (en) Carbohydrate degrading polypeptide and uses thereof
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
PH12017501520A1 (en) Fusarium toxin-cleaving polypeptide variants, additives containing same, use of same, and method for splitting fusarium toxins
MX340498B (es) Polipeptido heterodimerizado.
NZ781142A (en) Anti-vegf protein compositions and methods for producing the same
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
MX2021000328A (es) Enzimas de variantes de galactosa oxidasa modificadas geneticamente.
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
EP4374913A3 (en) Novel human serum albumin mutant
MY159074A (en) Polypeptide having d-lactate dehydrogenase activity, polynucleotide encoding the polypeptide, and process for production of d-lactic acid
PH12017502323A1 (en) Novel xylanase
MY169049A (en) Microorganisms for producing putrescine and process for producing putrescine using them
BR112022006842A2 (pt) Construtos de igf2 variante
PH12019501459A1 (en) Peptide for treating age-related macular degeneration
SA520420336B1 (ar) C أجسام مضادة مُطعمة بببتيد مدر للصوديوم من النوع
MX2022006385A (es) Acidos nucleicos, vectores, celulas huespedes y metodos para la produccion de beta-fructofuranosidasa a partir de aspergillus niger.
EA201692439A1 (ru) Пролин-специфичная эндопротеаза и ее применение